Anidulafungin In Treatment Of Candidemia In Asian Subjects

A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian Patients

The purpose of this study is to determine whether or not the Investigational Study Drug anidulafungin is safe and effective in the treatment of a fungal infection, candidemia, in Asian subjects.

Inclusion Criteria:

• Subjects with at least one positive blood test for Candida pathogen from a blood sample taken within 96 hours prior to start of study treatment.
• Subjects with clinical evidence of candida infection within 48 hours prior to enrollment.
• Acute Physiology and Chronic Health Enquiry (APACHE) score less than or equal to 20.

Exclusion Criteria:

• Prior exposure to systemic antifungals for more than 48 hours.
• Subjects who had, at any time, previously received anidulafungin.
• Subjects with poor venous (vein) access that would inhibit the administration of the intravenous study drug or withdrawing of multiple blood samples.
• Life expectancy < 72 hours.